Bausch Health Companies Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Bausch Health Companies Inc. (BHC) reported Cash and Cash Equivalents, Period Increase (Decrease) of $668.00 million for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-09.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2017-05-09
- Bausch Health Companies Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was $668.00M, a 6.31% decline year-over-year.
- Bausch Health Companies Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2016-09-30 was -$193.90M, a 141.97% decline year-over-year.
- Bausch Health Companies Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2016-06-30 was -$457.90M.
- Bausch Health Companies Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2016-03-31 was $713.00M, a 53.76% decline year-over-year.
- Bausch Health Companies Inc. cash and cash equivalents, period increase (decrease) for fiscal 2010 was $279.81M.
- Bausch Health Companies Inc. cash and cash equivalents, period increase (decrease) for fiscal 2009 was -$203.08M.
- Bausch Health Companies Inc. cash and cash equivalents, period increase (decrease) for fiscal 2008 was -$116.09M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 3 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|---|
| 2017-03-31 | $668.00M 10-Q · filed 2017-05-09 | ||||
| 2016-09-30 | -$193.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$651.80M derived: sum of 2 quarters · filed 2016-11-09 | $61.20M 10-Q · filed 2016-11-09 | ||
| 2016-06-30 | -$457.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $255.10M 10-Q · filed 2016-08-09 | |||
| 2016-03-31 | $713.00M 10-Q · filed 2017-05-09 | $713.10M 10-Q · filed 2016-06-07 | |||
| 2015-09-30 | $462.00M 10-Q · filed 2015-10-26 | -$444.40M derived: sum of 2 quarters · filed 2016-08-09 | $1.10B 10-Q · filed 2016-11-09 | ||
| 2015-06-30 | -$906.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $635.40M 10-Q · filed 2016-08-09 | |||
| 2015-03-31 | $1.54B 10-Q · filed 2016-06-07 | ||||
| 2014-09-30 | $277.60M 10-Q · filed 2015-10-26 | $208.50M 10-Q · filed 2015-10-26 | |||
| 2011-06-30 | -$162.81M 10-Q · filed 2011-08-08 | -$155.32M 10-Q · filed 2011-08-08 | -$353.71M derived: sum of 3 quarters · filed 2011-08-08 | $62.38M derived: sum of 4 quarters · filed 2011-08-08 | |
| 2011-03-31 | $7.48M 10-Q · filed 2011-05-10 | -$190.90M derived: sum of 2 quarters · filed 2011-05-10 | $225.19M derived: sum of 3 quarters · filed 2011-05-10 | $298.86M derived: sum of 4 quarters · filed 2011-08-08 | |
| 2010-12-31 | -$198.38M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-28 | $217.70M derived: sum of 2 quarters · filed 2011-02-28 | $291.38M derived: sum of 3 quarters · filed 2011-08-08 | $279.81M 10-K · filed 2011-02-28 | |
| 2010-09-30 | $416.09M 10-Q · filed 2010-11-05 | $489.76M derived: sum of 2 quarters · filed 2011-08-08 | $478.19M 10-Q · filed 2010-11-05 | $543.25M derived: sum of 4 quarters · filed 2011-08-08 | |
| 2010-06-30 | $73.67M 10-Q · filed 2011-08-08 | $62.10M 10-Q · filed 2011-08-08 | $127.16M derived: sum of 3 quarters · filed 2011-08-08 | $123.65M derived: sum of 4 quarters · filed 2011-08-08 | |
| 2010-03-31 | -$11.57M 10-Q · filed 2011-05-10 | $53.49M derived: sum of 2 quarters · filed 2011-05-10 | $49.97M derived: sum of 3 quarters · filed 2011-05-10 | -$194.80M derived: sum of 4 quarters · filed 2011-05-10 | |
| 2009-12-31 | $65.06M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-28 | $61.55M derived: sum of 2 quarters · filed 2011-02-28 | -$183.23M derived: sum of 3 quarters · filed 2011-02-28 | -$203.08M 10-K · filed 2011-02-28 | |
| 2009-09-30 | -$3.51M 10-Q · filed 2010-11-05 | -$248.29M derived: sum of 2 quarters · filed 2010-11-05 | -$268.14M 10-Q · filed 2010-11-05 | ||
| 2009-06-30 | -$244.78M 10-Q · filed 2010-08-06 | -$264.63M 10-Q · filed 2010-08-06 | |||
| 2008-12-31 | -$116.09M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |